Synucleins

A family of homologous proteins of low MOLECULAR WEIGHT that are predominately expressed in the BRAIN and that have been implicated in a variety of human diseases. They were originally isolated from CHOLINERGIC FIBERS of TORPEDO.

Also Known As:

Networked: 1780 relevant articles (26 outcomes, 153 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Masliah, Eliezer: 53 articles (01/2016 - 06/2003)
2.	Rockenstein, Edward: 25 articles (01/2015 - 06/2003)
3.	Halliday, Glenda M: 22 articles (10/2015 - 01/2011)
4.	Lashuel, Hilal A: 19 articles (01/2016 - 01/2010)
5.	Zhang, Jing: 18 articles (09/2015 - 03/2011)
6.	Brundin, Patrik: 17 articles (09/2015 - 11/2010)
7.	Dobson, Christopher M: 17 articles (09/2015 - 09/2010)
8.	Outeiro, Tiago F: 16 articles (11/2015 - 01/2011)
9.	Lee, Seung-Jae: 16 articles (07/2015 - 12/2010)
10.	Giasson, Benoit I: 16 articles (06/2015 - 02/2011)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2014 - "These data confirm that overexpression of Hsp70 holds significant potential as a disease-modulating therapeutic approach for Parkinson's disease, with protective effects against early-onset α-synuclein-induced pathology demonstrated in the AAV-α-synuclein model." 10/01/2014 - "Accumulation of α-synuclein plays a key role in the pathogenesis of Parkinson's disease (PD) and other synucleinopathies, suggesting that improved clearance of α-synuclein may be of therapeutic benefit. " 03/01/2013 - "Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease." 01/01/2015 - "The protein α-synuclein (α-Syn) has a central role in the pathogenesis of Parkinson's disease (PD) and immunotherapeutic approaches targeting this molecule have shown promising results. " 01/01/2015 - "Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease."
2.	Dementia (Dementias) 05/01/2010 - "Currently, contradictory data on the neuropathology of dementia in PD require further prospective clinicopathological studies in larger cohorts to elucidate the impact of AD and α-synuclein (SCNA) pathologies on the cognitive status in these disorders. " 07/01/2015 - "Regression analyses pointed to a combined pathology (Aβ plaque plus phosphotau plus α-synuclein-positive features), particularly in the prefrontal cortex (BA9) and temporal lobe neocortex with the superior and middle temporal gyrus (BA21, 22), being a major determining factor in the development of dementia. " 02/01/2015 - "These findings suggest that CSF oligomeric- and total-α-synuclein have different clinical, neuropsychological and MRI correlates across the proposed premotor-motor-dementia PD continuum. " 02/01/2015 - "CSF oligomeric-α-synuclein was higher in PDND than iRBD and in PDD than iRBD and controls, and correlated with UPDRS-III, MMSE, semantic fluency and visuo-perceptive scores across the proposed premotor-motor-dementia PD continuum (iRBD + PDND + PDD). " 02/01/2015 - "We determined CSF oligomeric- and total-α-synuclein in 77 subjects: 23 with idiopathic REM-sleep behaviour disorder (iRBD, a condition likely to include a remarkable proportion of subjects in the premotor stage of PD) and 41 with PD [21 non-demented (PDND) + 20 demented (PDD)], intended to reflect the premotor-motor-dementia PD continuum, along with 13 healthy controls. "
3.	Neurodegenerative Diseases (Neurodegenerative Disease) 01/01/2015 - "This study provides evidence for a novel interaction of α-synuclein and SOD1 that might be relevant for neurodegenerative diseases." 01/01/2015 - "To determine the performance of CSF α-synuclein as a diagnostic biomarker of PD and whether CSF α-synuclein can discriminate PD from other neurodegenerative diseases, a systematic search of all relevant studies investigating reproducible CSF α-synuclein quantification methods was conducted in electronic databases. " 06/07/2013 - "The current study suggests possible roles of α-synuclein aggregate and DAT distribution in the cytoplasm and synaptosome triggered by environmental toxins in later life in the development of neurodegenerative disorders. " 08/01/2011 - "Although previous studies have demonstrated the involvement of nitrated α-synuclein in neurodegenerative disorders (synucleinopathies), the effects of nitrated α-synuclein and the molecular mechanisms underlying its toxicity are still unclear. " 06/01/2011 - "2011; 14:399) described the importance of establishing the structural state of pathogenic protein aggregates (Aβ, α-synuclein, huntingtin, etc.) in studies of neurodegenerative disorders. "
4.	Disease Progression 07/01/2014 - "Further studies of α-synuclein's role in disease progression and long-term outcomes are needed." 11/01/2015 - "Viral vector-induced overexpression of α-synuclein in dopaminergic neurons represents a model of PD which recapitulates disease progression better than commonly used neurotoxin models. " 09/15/2015 - "The neuropathological hallmark of PD is intraneuronal inclusions containing primarily α-Synuclein (α-Syn), and several lines of evidence point to α-Syn as a key contributor to disease progression. " 01/12/2015 - "Synucleinopathies are neurodegenerative pathologies in which disease progression is closely correlated to brain accumulation of insoluble α-synuclein, a small protein abundantly expressed in neural tissue. " 01/01/2015 - "Interneuronal propagation of α-synuclein has been demonstrated in a variety of experimental models and may be involved in disease progression during the course of human synucleinopathies. "
5.	Inflammation 10/28/2014 - "In LIMP-2-deficient brains a significant reduction in GC activity led to lipid storage, disturbed autophagic/lysosomal function, and α-synuclein accumulation mediating neurotoxicity of dopaminergic (DA) neurons, apoptotic cell death, and inflammation. " 04/01/2015 - "Importantly, recent preclinical studies are now suggesting a specific contribution of inflammation to the α-synuclein-induced pathology seen in this condition. " 01/01/2014 - "Previous studies have shown that extracellular α-synuclein aggregates can activate microglial cells, induce inflammation and contribute to the neurodegenerative process in PD. " 08/07/2015 - "We found that rats expressing G2019S-LRRK2 have exacerbated dopaminergic neurodegeneration and inflammation in response to the overexpression of α-synuclein. " 05/01/2015 - "These results suggest α-synuclein as a pathological link between chronic effects of TBI and PD symptoms as evidenced by significant overexpression and abnormal accumulation of α-synuclein in inflammation-infiltrated SN of rats exposed to chronic TBI."

Related Drugs and Biologics

1.	Amyloid (Amyloid Fibrils)
2.	Curcumin
3.	Dopamine (Intropin)
4.	Oxidopamine (6 Hydroxydopamine)
5.	alpha-Synuclein
6.	Ubiquitin
7.	Prions
8.	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)
9.	Immunoglobulin G (IgG)
10.	antineoplaston A10 (A 10)

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Therapeutics
4.	Denervation
5.	Oral Administration